KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EPS (Weighted Average and Diluted): 2009-2025

Historic EPS (Weighted Average and Diluted) for Teva Pharmaceutical Industries (TEVA) over the last 14 years, with Sep 2025 value amounting to $0.37.

  • Teva Pharmaceutical Industries' EPS (Weighted Average and Diluted) rose 194.87% to $0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.60, marking a year-over-year increase of 170.59%. This contributed to the annual value of -$1.45 for FY2024, which is 190.00% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported EPS (Weighted Average and Diluted) of $0.37 as of Q3 2025, which was up 54.17% from $0.24 recorded in Q2 2025.
  • Teva Pharmaceutical Industries' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.41 during Q4 2023, with a 5-year trough of -$1.17 in Q4 2022.
  • For the 3-year period, Teva Pharmaceutical Industries' EPS (Weighted Average and Diluted) averaged around -$0.11, with its median value being -$0.12 (2024).
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 1,328.57% in 2022, then spiked by 250.00% in 2025.
  • Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' EPS (Weighted Average and Diluted) stood at -$0.14 in 2021, then tumbled by 735.71% to -$1.17 in 2022, then surged by 135.04% to $0.41 in 2023, then slumped by 146.34% to -$0.19 in 2024, then spiked by 194.87% to $0.37 in 2025.
  • Its EPS (Weighted Average and Diluted) was $0.37 in Q3 2025, compared to $0.24 in Q2 2025 and $0.18 in Q1 2025.